Manhattan Scientifics Inc Overview
Pro stress-test →Manhattan Scientifics Inc is a technology incubator and nano-technology commercialization company focused on acquiring, developing, and commercializing life-enhancing technologies in nanotechnology and nanomedicine. The company operates two primary ventures: nanomedicine cancer detection technology (through majority ownership of Imagion Biosystems Ltd) and nanostructured metal alloys for medical and industrial applications.
Strategic Profile
Pro stress-test →The company operates as an intellectual property and technology licensing model, leveraging strategic partnerships with major research institutions including MD Anderson Cancer Center and University of New Mexico Health Sciences Center. Manhattan Scientifics holds significant equity stakes in spinoff companies and derives value primarily through technology transfer and commercialization rather than direct operations.
Competitive Landscape
Pro stress-test →Manhattan Scientifics competes in fragmented nanomedicine and nanotech markets against significantly larger, better-capitalized biotechnology firms. Its primary competitive advantage is early intellectual property in nanomagnetic cancer detection and nanostructured metals. Competitors in cancer diagnostics include Guardant Health, Foundation Medicine, and larger in-vitro diagnostics companies; metal alloy markets face competition from established materials science firms.
Industry Context
Manhattan Scientifics Inc operates in Biotechnology / Nanomedicine.
Key facts
Founded: 1992 · Headquarters: New York, US · Market cap: $55.9K